Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines

• Published in: Cancer cell international Vol. 6; no. 1; p. 2
• Main Authors: Chavez-Blanco, Alma, Perez-Plasencia, Carlos, Perez-Cardenas, Enrique, Carrasco-Legleu, Claudia, Rangel-Lopez, Edgar, Segura-Pacheco, Blanca, Taja-Chayeb, Lucia, Trejo-Becerril, Catalina, Gonzalez-Fierro, Aurora, Candelaria, Myrna, Cabrera, Gustavo, Duenas-Gonzalez, Alfonso
• Format: Journal Article
• Language: English
• Published: England National Library of Medicine - MEDLINE Abstracts 31-01-2006; BioMed Central Ltd; BioMed Central; BMC
• Subjects: Primary Research
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/1475-2867-6-2

Among the epigenetic alterations occurring in cancer, DNA hypermethylation and histone hypoacetylation are the focus of intense research because their pharmacological inhibition has shown to produce antineoplastic activity in a variety of experimental models. The objective of this study was to evaluate the combined antineoplastic effect of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in a panel of cancer cell lines.
Hydralazine showed no growth inhibitory effect on cervical, colon, breast, sarcoma, glioma, and head & neck cancer cell lines when used alone. On the contrary, valproic acid showed a strong growth inhibitory effect that is potentiated by hydralazine in some cell lines. Individually, hydralazine and valproic acid displayed distinctive effects upon global gene over-expression but the number of genes over-expressed increased when cells were treated with the combination. Treatment of HeLa cells with hydralazine and valproic acid lead to an increase in the cytotoxicity of gemcitabine, cisplatin and adriamycin. A higher antitumor effect of adriamycin was observed in mice xenografted with human fibrosarcoma cells when the animals were co-treated with hydralazine and valproic acid.
Hydralazine and valproic acid, two widely used drugs for cardiovascular and neurological conditions respectively have promising antineoplastic effects when used concurrently and may increase the antitumor efficacy of current cytotoxic agents.